Intelligence / Healthtech / New Clinical Trials / AstraZeneca
AstraZeneca
22 Oct 2026: Trial registered · Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable Plexiform Neurofibroma (PN). Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 22 Oct 2026
- Title
- Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable Plexiform Neurofibroma (PN)
- Conditions
- Neurofibromatosis Type 1 (NF1)
- Study Type
- Observational
- Status
- Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07888517
- Location
- China
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at AstraZeneca
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for AstraZeneca in our registers.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.